Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

COVID-19 Front-Burner, Broad-Spectrum Anti-viral Back-Burner, Sheer, Genius Leo

Company advancing Brilacidin as a next-generation broad-spectrum antiviral for the treatment of common colds and deadly coronavirus infections
.... Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs. On completion of testing, the H-CoV findings are expected to be submitted for peer-review publication. The Company is evaluating these data alongside previously obtained SARS-CoV-2 data, strategizing with its scientific advisors and consultants, to develop Brilacidin as a “pan-coronavirus” therapeutic.

http://www.ipharminc.com/press-release/2020/11/30/innovation-pharmaceuticals-covid-19-clinical-trial-to-support-additional-development-of-brilacidin-as-a-pan-coronavirus-therapeutic

I believe this quote signaled Leo's change FROM IBD, as the lead area of focus for Brilacidin, TO Anti-Viral Drug Therapy. Here's why:

The global anti-viral drug therapy market reached a value of nearly $46,456.4 million [=$46.4B] in 2019, having increased at a compound annual growth rate (CAGR) of 5.0% since 2015. The market is expected to grow from $46,456.4 million [=$46.4B] in 2019 to $ 61,571.9 million [=$61.5B] in 2020 at a rate of 32.5%. The growth is mainly due to the increase in number of COVID-19 cases. The market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74,385.9 million [=$74.3B] in 2023. The market is expected to reach $ 87,230.5 million [=$87.2B] in 2025, and $ 130,125.3 million [=$130.1B] in 2030. [equivalency added]

https://www.businesswire.com/news/home/20210210005504/en/Global-Anti-Viral-Drug-Therapy-Market-2020-to-2030---Opportunities-and-Strategies-with-COVID-19-Implications-and-Growth---ResearchAndMarkets.com

The beauty of the development of 'B' for AVDT is that the researchers are excited about doing the "broad-spectrum" research based on what they observed in the B-COVID research. Additionally, the pandemic has motivated governments to invest more money in research for vaccines and AVDTs.

By comparison:

The global inflammatory bowel disease treatment market size is expected to reach USD 22.4 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.4% CAGR during the forecast period. Increasing prevalence and incidence of Crohn’s disease and ulcerative colitis is one of the major factors contributing to the market.

https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm_source=blog.goo.ne.jp&utm_medium=referral&utm_campaign=Vrushali_7Aug_hc_InflammatoryBowelDiseaseTreatmentMarket_pr&utm_content=Content

Sometimes following Leo's thinking is as simple as following the money. In 2030, the projected anti-viral drug therapy (AVDT) market size will be nearly 6-times the market size of IBD in 2026, suggesting that between 2021 -2030, the AVDT market will be the much, much, more lucrative area of the two.

Normally, I would say given these facts and projections, IBD must take a backseat to AVDT. BUT, if you will click on the reference post# above, you can read why I believe B-COVID will be able to provide all the financing needed for development of AVDT, IBD and the rest of IPIX's pipeline...simultaneously.